Exosomes derived from MSCs ameliorate retinal laser injury partially by inhibition of MCP-1

Area of Science:

• Ophthalmology
• Regenerative Medicine
• Cell Biology

Background:

• Mesenchymal stem cells (MSCs) exert therapeutic effects via paracrine signaling, but mechanisms remain unclear.
• MSC-derived exosomes (MSC-Exos) are emerging as key mediators, delivering functional molecules to target cells.
• Laser-induced retinal injury is a model to study therapeutic interventions for retinal damage.

Purpose of the Study:

• To compare the therapeutic efficacy of MSCs and MSC-Exos in a mouse model of laser-induced retinal injury.
• To investigate the underlying mechanisms of MSC-Exo-mediated retinal protection, focusing on inflammatory pathways.

Main Methods:

• Intravitreal injection of adipose-derived MSCs, umbilical cord-derived MSCs, and their exosomes in mice with laser-induced retinal injury.
• Assessment of visual function, apoptosis, and inflammatory markers (MCP-1) in retinal tissues.
• In vitro studies on primary cultured retinal cells to evaluate MCP-1 mRNA expression.
• Administration of MCP-1-neutralizing antibody alongside MSC-Exos.

Main Results:

• Both MSCs and MSC-Exos significantly reduced retinal damage, inhibited apoptosis, and suppressed inflammation, leading to improved visual function.
• MSC-Exos notably down-regulated monocyte chemotactic protein-1 (MCP-1) levels in the retina both in vivo and in vitro.
• Neutralization of MCP-1 promoted retinal recovery, and co-administration with MSC-Exos abolished the exosomes' therapeutic effect.

Conclusions:

• MSC-Exos demonstrate significant therapeutic potential for laser-induced retinal injury, comparable to parental MSCs.
• The protective effects of MSC-Exos are, in part, attributed to the down-regulation of MCP-1.
• These findings highlight MSC-Exos as promising cell-free therapeutic agents for retinal diseases.